Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450004 | 0.81 | MAPT (0.62) | TDP1KDM4EMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL11038905 | 0.81 | MAPT (0.62) | TDP1KDM4EMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL29451077 | 0.81 | TDP1 (1.00) | TDP1KDM4EPKMMAPTL3MBTL1 | |
| SCHEMBL116696 | 0.81 | TDP1 (1.00) | TDP1KDM4EPKMMAPTL3MBTL1 | |
| SCHEMBL382385 | 0.81 | MAPT (0.62) | TDP1KDM4EMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL9078409 | 0.76 | NQO2 (0.46) | TDP1KDM4EPKMMAPTALDH1A1 | |
| SCHEMBL11206926 | 0.75 | TDP1 (0.75) | TDP1KDM4EPKMMAPTL3MBTL1 | |
| Bicarbonate SCHEMBL10870596 | 0.75 | TDP1 (0.75) | TDP1KDM4EPKMMAPTL3MBTL1 | |
| SCHEMBL1560774 | 0.74 | ALDH1A1 (0.39) | TDP1KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL9157834 | 0.73 | TDP1 (0.71) | TDP1KDM4EPKMMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100345831-C | Prepn process of high purity 2, 6-dichloro quinoxaline | WU YONGHU (CN) | 2007-10-31 | — | — | CN | claimed |
| CN-1772742-A | Prepn process of high purity 2, 6-dichloro quinoxaline | WU YONGHU (CN) | 2006-05-17 | — | — | CN | claimed |
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| EP-2880033-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2459582-B1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2008057209-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| CN-100345831-C | Prepn process of high purity 2, 6-dichloro quinoxaline | WU YONGHU (CN) | 2007-10-31 | — | — | CN | disclosed |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| CN-1772742-A | Prepn process of high purity 2, 6-dichloro quinoxaline | WU YONGHU (CN) | 2006-05-17 | — | — | CN | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
| WO-1991001977-A1 | PROCESS FOR PREPARING 2,6-DICHOLOROQUINOXALINE | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-02-21 | — | — | WO | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4083977-A | Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas | ELI LILLY AND COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | TDP1 167/4885KDM4E 2755/4885PKM 3024/4885 |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | TDP1 3107/4885KDM4E 2747/4885PKM 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.